3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead
Michael Soth1, Sarah Abbot, Allassan Abubakari
1Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304, USA. michael.soth@roche.com
Bioorganic & Medicinal Chemistry Letters
|April 26, 2011
Abstract:
Learnings from previous Roche p38-selective inhibitors were applied to a new fragment hit, which was optimized to a potent, exquisitely selective preclinical lead with a good pharmacokinetic profile.


